---
title: "New Publication Further Validates Capitainer Technology for Remote Alzheimer's Disease Biomarker Testing"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287178498.md"
description: "On May 21, 2026, in Stockholm, a recent study published in Nature Communications reveals that capillary blood samples collected remotely can effectively measure Alzheimer's disease biomarkers linked to cognitive decline and function in older individuals. This breakthrough offers promising implications for early detection and monitoring of the disease. The study highlights the potential benefits of utilizing this method for diagnosing Alzheimer's, potentially impacting the lives of millions worldwide."
datetime: "2026-05-21T07:37:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287178498.md)
  - [en](https://longbridge.com/en/news/287178498.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287178498.md)
generator: "portal-rs"
---

# New Publication Further Validates Capitainer Technology for Remote Alzheimer's Disease Biomarker Testing

On May 21, 2026, in Stockholm, a recent study published in Nature Communications reveals that capillary blood samples collected remotely can effectively measure Alzheimer's disease biomarkers linked to cognitive decline and function in older individuals. This breakthrough offers promising implications for early detection and monitoring of the disease. The study highlights the potential benefits of utilizing this method for diagnosing Alzheimer's, potentially impacting the lives of millions worldwide.

### Related Stocks

- [000863.CN](https://longbridge.com/en/quote/000863.CN.md)

## Related News & Research

- [Bioz and InvivoGen Elevate Scientific Discovery with an Expanded Digital Research Experience](https://longbridge.com/en/news/296322409.md)
- [Bioz and Xenocs Improve Researcher Product Evaluation Through On-Page Publication Insights](https://longbridge.com/en/news/296195684.md)
- [Revive Therapeutics Outlines Strategy to Build a Biodefence and Pandemic Preparedness Therapeutics Portfolio | RVVTF Stock News](https://longbridge.com/en/news/296357987.md)
- [04:20 ETSphingoTec to Engage with Clinical and Industry Partners at Major 2026 Conferences](https://longbridge.com/en/news/296322953.md)
- [BioNxt completes IMPD, moves toward first human bioequivalence trial for sublingual cladribine film in MS](https://longbridge.com/en/news/296314929.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**